Ferrer Darío G, Jaldín-Fincati Javier R, Amigone José L, Capra Raul H, Collino César J, Albertini Ricardo A, Chiabrando Gustavo A
Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.
Cytometry A. 2014 Jul;85(7):601-10. doi: 10.1002/cyto.a.22455. Epub 2014 Mar 17.
In this article, we present a flow cytometry assay by which human blood monocyte subpopulations-classical (CD14(++) CD16(-)), intermediate (CD14(++) CD16(+)), and nonclassical (CD14(+) CD16(++)) monocytes-can be determined. Monocytic cells were selected from CD45(+) leukocyte subsets by differential staining of the low-density lipoprotein receptor-related protein 1 (LRP1), which allows reducing the spill-over of natural killer cells and granulocytes into the CD16(+) monocyte gate. Percentages of monocyte subpopulations established by this procedure were significantly comparable with those obtained by a well-standardized flow cytometry assay based on the HLA-DR monocyte-gating strategy. We also demonstrated that LRP1 is differentially expressed at cell surface of monocyte subpopulations, being significantly lower in nonclassical monocytes than in classical and intermediate monocytes. Cell surface expression of LRP1 accounts for only 20% of the total cellular content in each monocyte subpopulation. Finally, we established the within-individual biological variation (bCV%) of circulating monocyte subpopulations in healthy donors, obtaining values of 21%, 20%, and 17% for nonclassical, intermediate, and classical monocytes, respectively. Similar values of bCV% for LRP1 measured in each monocyte subpopulation were also obtained, suggesting that its variability is mainly influenced by the intrinsic biological variation of circulating monocytes. Thus, we conclude that LRP1 can be used as a third pan-monocytic marker together with CD14 and CD16 to properly identify monocyte subpopulations. The combined determination of monocyte subpopulations and LRP1 monocytic expression may be relevant for clinical studies of inflammatory processes, with special interest in atherosclerosis and cardiovascular disease.
在本文中,我们介绍了一种流式细胞术检测方法,通过该方法可以确定人类血液单核细胞亚群——经典型(CD14(++) CD16(-))、中间型(CD14(++) CD16(+))和非经典型(CD14(+) CD16(++))单核细胞。通过对低密度脂蛋白受体相关蛋白1(LRP1)进行差异染色,从CD45(+)白细胞亚群中选择单核细胞,这可以减少自然杀伤细胞和粒细胞向CD16(+)单核细胞门的溢出。通过该程序确定的单核细胞亚群百分比与基于HLA-DR单核细胞门控策略的标准化良好的流式细胞术检测所获得的百分比具有显著可比性。我们还证明,LRP1在单核细胞亚群的细胞表面差异表达,在非经典单核细胞中显著低于经典和中间单核细胞。LRP1的细胞表面表达仅占每个单核细胞亚群总细胞含量的20%。最后,我们确定了健康供体中循环单核细胞亚群的个体内生物学变异(bCV%),非经典、中间和经典单核细胞的值分别为21%、20%和17%。在每个单核细胞亚群中测量的LRP1的bCV%也获得了相似的值,表明其变异性主要受循环单核细胞内在生物学变异的影响。因此,我们得出结论,LRP1可以与CD14和CD16一起用作第三种全单核细胞标志物,以正确识别单核细胞亚群。单核细胞亚群和LRP1单核细胞表达的联合测定可能与炎症过程的临床研究相关,对动脉粥样硬化和心血管疾病特别感兴趣。